Previous 10 | Next 10 |
Nanobiotix S.A. (NBTX) is expected to report for Q2 2023
PARIS and CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with...
PARIS and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities f...
2023-08-24 08:40:40 ET Summary Nanobiotix is an oncology-focused biotech aiming for its first drug approval, with a tripled value since the beginning of 2023. Their flagship molecule, NBTX3-RT, is showing promising results in enhancing the efficacy of radiotherapy for various soli...
2023-08-24 08:36:21 ET Summary Nanobiotix has signed a major deal with Janssen, granting Janssen global licensing, co-development, and commercialization rights for its lead asset NBTXR3. The deal includes upfront cash and operational support valued up to $60 million for Nanobiotix...
PARIS and CAMBRIDGE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
2023-08-07 08:34:22 ET Missfresh ( MF ) +51% a nnounces Entry into Share Transfer Agreement. Sequans Communications ( SQNS ) +31% Q2 earnings call release Tabula Rasa HealthCare ( TRHC ) +30% Reports Second Quarter 2023 Financial Results. ...
PARIS and CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for...
2023-07-25 08:22:48 ET NeuroOne Medical Technologies Corporation ( NMTC ) -35% . announces pricing of public offering of common stock . Stoke Therapeutics ( STOK ) -34% announces positive new safety & efficacy data from patients treated with STK-001 in the ...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...